相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Charles G. Drake et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Update on Immune Checkpoint Inhibitors in Lung Cancer
Benjamin C. Creelan
CANCER CONTROL (2014)
Newer developments in the immunotherapy of malignant melanoma
Benjamin Maslin et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Frank R. Brennan et al.
MABS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Axel Hoos et al.
SEMINARS IN ONCOLOGY (2010)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host
Hirohisa Yazaki et al.
TRANSPLANTATION (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
The calm after the cytokine storm: lessons from the TGN1412 trial
E. William St. Clair
JOURNAL OF CLINICAL INVESTIGATION (2008)
Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
分享论文
